Impact of Value-Driven Healthcare Strategies for Biosimilar Adoption: The Singapore Story.

IF 2 Q2 ECONOMICS PharmacoEconomics Open Pub Date : 2024-09-01 Epub Date: 2024-07-23 DOI:10.1007/s41669-024-00491-w
She Hui Tan, Louise Gek Huang Goh, Benjamin Shao Kiat Ong, Darren Sze Guan Ng, Liang Lin, Raymond Chee Hui Ng, Bernard Yu-Hor Thong, Kwong Ng
{"title":"Impact of Value-Driven Healthcare Strategies for Biosimilar Adoption: The Singapore Story.","authors":"She Hui Tan, Louise Gek Huang Goh, Benjamin Shao Kiat Ong, Darren Sze Guan Ng, Liang Lin, Raymond Chee Hui Ng, Bernard Yu-Hor Thong, Kwong Ng","doi":"10.1007/s41669-024-00491-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Healthcare sustainability is a global challenge. Various value-driven healthcare strategies have been implemented by Singapore's national health technology assessment (HTA) agency, the Agency for Care Effectiveness (ACE). Considering the high and growing expenditure on biologics, strategies have been implemented to drive the use of biosimilars. As Singapore has reached the 5-year mark since the subsidy listing of the first monoclonal antibody biosimilar infliximab, this review aimed to evaluate the impact of these strategies on the changes in adoption rates, utilisation, spending and cost savings for biosimilars in the public healthcare sector.</p><p><strong>Methods: </strong>A retrospective cross-sectional study was conducted using aggregated drug utilisation data from all public healthcare institutions. Five monoclonal antibodies with biosimilars, namely infliximab, adalimumab, trastuzumab, rituximab and bevacizumab, were included in this study. The outcomes evaluated were the monthly trends for utilisation volume, proportion attributed to biosimilar use, and drug spending up to December 2022. The simulated cost savings associated with biosimilar adoption were also reported.</p><p><strong>Results: </strong>After subsidy implementation, an upward trend in biosimilar use and proportion attributed to biosimilar adoption was observed, while spending reduced substantially. The adoption rate of most biosimilars reached more than 95% within 1 year of listing. Drugs with more than one approved biosimilar brand at the time of subsidy listing reported substantial price reductions of over 80%. Overall, spending for the five monoclonal antibodies have significantly reduced after biosimilar subsidy listing, with an estimated cumulative cost savings of $136 million over 5 years.</p><p><strong>Conclusion: </strong>Value-driven healthcare strategies implemented in Singapore's public healthcare institutions have contributed to high adoption rates of biosimilars and have improved affordable access through lower treatment costs. This in turn has led to significant cost savings to the healthcare system.</p>","PeriodicalId":19770,"journal":{"name":"PharmacoEconomics Open","volume":" ","pages":"679-688"},"PeriodicalIF":2.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11362392/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s41669-024-00491-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Healthcare sustainability is a global challenge. Various value-driven healthcare strategies have been implemented by Singapore's national health technology assessment (HTA) agency, the Agency for Care Effectiveness (ACE). Considering the high and growing expenditure on biologics, strategies have been implemented to drive the use of biosimilars. As Singapore has reached the 5-year mark since the subsidy listing of the first monoclonal antibody biosimilar infliximab, this review aimed to evaluate the impact of these strategies on the changes in adoption rates, utilisation, spending and cost savings for biosimilars in the public healthcare sector.

Methods: A retrospective cross-sectional study was conducted using aggregated drug utilisation data from all public healthcare institutions. Five monoclonal antibodies with biosimilars, namely infliximab, adalimumab, trastuzumab, rituximab and bevacizumab, were included in this study. The outcomes evaluated were the monthly trends for utilisation volume, proportion attributed to biosimilar use, and drug spending up to December 2022. The simulated cost savings associated with biosimilar adoption were also reported.

Results: After subsidy implementation, an upward trend in biosimilar use and proportion attributed to biosimilar adoption was observed, while spending reduced substantially. The adoption rate of most biosimilars reached more than 95% within 1 year of listing. Drugs with more than one approved biosimilar brand at the time of subsidy listing reported substantial price reductions of over 80%. Overall, spending for the five monoclonal antibodies have significantly reduced after biosimilar subsidy listing, with an estimated cumulative cost savings of $136 million over 5 years.

Conclusion: Value-driven healthcare strategies implemented in Singapore's public healthcare institutions have contributed to high adoption rates of biosimilars and have improved affordable access through lower treatment costs. This in turn has led to significant cost savings to the healthcare system.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
价值驱动型医疗保健战略对采用生物仿制药的影响:新加坡的故事。
背景:医疗保健的可持续性是一项全球性挑战。新加坡的国家卫生技术评估(HTA)机构--护理效果局(ACE)实施了各种以价值为导向的医疗保健战略。考虑到生物制剂的支出很高,而且还在不断增长,因此实施了推动使用生物仿制药的战略。自首个单克隆抗体生物仿制药英夫利昔单抗获得补贴上市以来,新加坡已经走过了 5 个年头,本综述旨在评估这些策略对生物仿制药在公共医疗领域的采用率、使用率、支出和成本节约方面的变化所产生的影响:方法:利用所有公立医疗机构的药物使用汇总数据进行了一项回顾性横断面研究。五种单克隆抗体的生物仿制药,即英夫利昔单抗、阿达木单抗、曲妥珠单抗、利妥昔单抗和贝伐珠单抗被纳入了这项研究。评估的结果是截至 2022 年 12 月的每月使用量趋势、生物仿制药使用比例和药物支出。研究还报告了采用生物仿制药所节省的模拟成本:补贴实施后,生物仿制药的使用量和采用生物仿制药的比例呈上升趋势,而支出则大幅减少。大多数生物仿制药的采用率在上市后一年内达到 95% 以上。在补贴上市时,拥有一个以上获批生物仿制药品牌的药品价格大幅下降了 80% 以上。总体而言,在生物仿制药补贴上市后,五种单克隆抗体的支出大幅减少,5 年内估计累计节省成本 1.36 亿美元:结论:新加坡公共医疗机构实施的价值驱动型医疗保健战略促使生物仿制药的采用率提高,并通过降低治疗成本改善了可负担得起的就医途径。这反过来又为医疗系统节省了大量成本。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
64
审稿时长
8 weeks
期刊介绍: PharmacoEconomics - Open focuses on applied research on the economic implications and health outcomes associated with drugs, devices and other healthcare interventions. The journal includes, but is not limited to, the following research areas:Economic analysis of healthcare interventionsHealth outcomes researchCost-of-illness studiesQuality-of-life studiesAdditional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in PharmacoEconomics -Open may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.
期刊最新文献
Incorporating Resource Constraints in Health Economic Evaluations: Overview and Methodological Considerations. Health-Economic Modelling of Improved Behavior in Insulin Injection Technique in Belgium. Comparing Different Implementation Strategies for Collaborative Dementia Care Management in Terms of Patients' Characteristics, Unmet Needs, and the Impact on Quality of Life and Costs in Germany. Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year Data. Economic Evaluation of Total Knee Replacement Compared with Non-Surgical Management for Knee Osteoarthritis in India.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1